Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib

Sabine Schmid; Erin L Stewart; Sebastiao N Martins-Filho; Michael Cabanero; Ao Wang; Hua Bao; Xue Wu; Deval Patel; Zhuo Chen; Jennifer H Law; Penelope A Bradbury; Frances A Shepherd; Natasha Leighl; Ming-Sound Tsao; Trevor Pugh; Scott V Bratman; Adrian Sacher; Geoffrey Liu

doi:10.1016/j.cllc.2020.03.009

Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib

Clin Lung Cancer. 2020 Sep;21(5):e488-e492. doi: 10.1016/j.cllc.2020.03.009. Epub 2020 Apr 9.

Authors

Sabine Schmid¹, Erin L Stewart², Sebastiao N Martins-Filho³, Michael Cabanero³, Ao Wang⁴, Hua Bao⁴, Xue Wu⁴, Deval Patel², Zhuo Chen², Jennifer H Law², Penelope A Bradbury¹, Frances A Shepherd¹, Natasha Leighl¹, Ming-Sound Tsao⁵, Trevor Pugh⁶, Scott V Bratman⁷, Adrian Sacher⁸, Geoffrey Liu⁹

Affiliations

¹ University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
² University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada.
³ University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
⁴ Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, ON, Canada.
⁵ University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
⁶ University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
⁷ University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
⁸ University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.
⁹ University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada. Electronic address: [email protected].

PMID: 32389504
DOI: 10.1016/j.cllc.2020.03.009

No abstract available

Keywords: Liquid biopsy; Molecular clones; Small-cell transformation; Treatment adaption; Treatment monitorin.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Acrylamides / therapeutic use*
Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Adenocarcinoma of Lung / pathology
Aniline Compounds / therapeutic use*
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / genetics*
Circulating Tumor DNA / analysis
Circulating Tumor DNA / genetics*
Drug Resistance, Neoplasm*
ErbB Receptors / genetics
Female
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Middle Aged
Mutation*
Prognosis

Substances

Acrylamides
Aniline Compounds
Antineoplastic Agents
Biomarkers, Tumor
Circulating Tumor DNA
osimertinib
EGFR protein, human
ErbB Receptors